Most Clicked SNMMI SmartBrief Stories


1. Navidea touts new radiotracer for beta amyloid imaging

SNMMI SmartBrief | Jul 27, 2015

Navidea Biopharmaceuticals' fluorine-based radiotracer NAV4694 is now in Phase II and III clinical trials, and company officials say its strong performance coupled with simpler logistics than C-11 Pittsburgh B compound indicate a promising future for the agent. If approved, the radiotracer will be useful in identifying patients for clinical trials and facilitating earlier treatment, said Chief Medical Officer Dr. Michael Tomblyn and Senior Director of Clinical Operations David Colborn. BioPharma Dive (07/24)


2. Perma-Fix, Digirad ink deal on new Tc-99m production platform

SNMMI SmartBrief | Jul 28, 2015

Digirad invested $1 million in a partnership with Perma-Fix Medical to produce technetium-99m. Perma-Fix Medical is developing technology to manufacture Tc-99m without uranium. The deal will allow Digirad to buy Tc-99m from Perma-Fix at a preferred rate once the new approach is in use. AuntMinnie.com (free registration) (07/27)


3. Is cancer simply a consequence of life?

SNMMI SmartBrief | Jul 29, 2015

Cancerlike phenomena occur in organisms of all types as cells dance between competition and cooperation, according to research reported in Philosophical Transactions B. Rogue cells abandon their scripted roles in a given tissue type, undergoing "dedifferentiation," and those that develop into cancer escape biological protections designed to stop such proliferation. These cells behave pathologically to establish their own ecosystems, ultimately at their own expense. The team characterized growths in corals, mushrooms and cacti as cancerlike. The New York Times (free-article access for SmartBrief readers) (07/27)


4. FDA to check safety risk of gadolinium deposits in brain

SNMMI SmartBrief | Jul 28, 2015

The FDA's National Center for Toxicological Research plans to investigate the risk of gadolinium-based contrast agents after several reports indicated residual gadolinium may persist in the brains of patients who received multiple contrast-enhanced MRI scans. It is not known whether gadolinium deposits present any adverse health effects, the FDA said, but it urged providers to re-evaluate treatment protocols for repetitive GBCA MRIs. AuntMinnie.com (free registration) (07/27) Medscape (free registration) (07/27)


5. Study: Radiotherapy for breast cancer may damage heart

SNMMI SmartBrief | Jul 30, 2015

Heart damage results from even low-dose radiotherapy used to treat breast cancer, according to a study presented at a meeting of the American Association of Physicists in Medicine. The canine study used radiation designed to mirror exposure during left breast radiotherapy, and they observed myocardial inflammation and perfusion using PET/MRI with FDG and N-13 ammonia dynamic PET. "Even areas that were barely irradiated showed damage," said researcher Omar El-Sherif, concluding that doses of less than 2 Gy can cause a global inflammatory response and myocardial perfusion defects. Medical Physics Web (registration required) (07/28)


6. Study: Anti-amyloid drug clears buildup, but effect on cognition is unclear

SNMMI SmartBrief | Jul 29, 2015

An analysis of PET data indicates bapineuzumab cleared amyloid buildup from the brains of patients with Alzheimer's disease, even while no clinical benefit was found in trials. The findings "raise the possibility that bapineuzumab immunotherapy could have a greater effect on amyloid accumulation in patients treated earlier in the disease course," researchers wrote in the journal Neurology. However, an accompanying commentary questioned whether the continued pursuit of anti-amyloid drugs is the best use of resources. MedPage Today (free registration) (07/28)


7. Study finds Alzheimer's misdiagnosis carries heavy cost

SNMMI SmartBrief | Jul 29, 2015

A study in Alzheimer's and Dementia found Medicare patients who are misdiagnosed with Alzheimer's disease accrue an additional $9,500 to $14,000 in annual care costs. Patients who were mistakenly told they had Alzheimer's instead of vascular dementia or Parkinson's disease used more skilled nursing and home health care and had more hospital and physician visits, as well as additional claims for durable medical equipment. McKnight's Long-Term Care News (07/27)


8. Navidea radiopharmaceutical study receives grant from NIH

SNMMI SmartBrief | Jul 29, 2015

The NIH's National Heart, Lung, and Blood Institute has awarded Navidea Biopharmaceuticals a $321,000 grant to investigate the potential of Navidea's technetium-99m tilmanocept in detecting cardiovascular disease. Navidea will collaborate with Harvard Medical School and Massachusetts General Hospital on the research. AuntMinnie.com (free registration) (07/28)


9. NIST develops technique to improve calibration of commercial PET phantoms

SNMMI SmartBrief | Jul 30, 2015

The National Institute of Standards and Technology has developed a calibration method for a phantom device built by Sanders Medical Products that addresses some sources of error by directly measuring germanium content. Sanders Medical Products supplies phantoms that come with PET/MRI machines from GE Healthcare. "Doctors are realizing putting effort into this kind of quantitative work can reveal differences of 5% in tumor size, rather than the 20% they look for now," said researcher Brian Zimmerman. PhysOrg.com (07/29)


10. Study locates area of brain that sets humans apart

SNMMI SmartBrief | Jul 27, 2015

A part of the brain that sets humans apart from other creatures has been identified in a study that compared brain activity in humans and monkeys in response to abstract information. Scientists observed brain activity when human subjects and monkeys listened to simple musical patterns and noted that the inferior frontal gyrus lit up in functional MRI scans of human brains when the music patterns became more complicated. Nature (free content) (07/23)




Sign up for SNMMI SmartBrief



Designed specifically for nuclear medicine and molecular imaging professionals, SNMMI SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news and information to save you time and keep you informed on our profession. Learn more